Professor Steve Henry is an academic with a difference. Like other professors, research is his professional life, but unlike many he believes commercialisation is an integral partner to successful research. Having trained as a laboratory scientist specialising in transfusion medicine, Steve completed a PhD at the University of Auckland and completed another PhD in the 1990s. In 1996 he started the biotechnology company Kode Biotech to commercialise his biosurface engineering technology - Kode technology. As the CEO of Kode Biotech and Professor in the AUT Centre for Kode Technology Innovation he is fully immersed in the true commercial environment, taking research to product and developing it for the market. In 2015 Kode Biotech won the Supreme NZ Innovator Award for their contribution to the Agalimmune anti-cancer therapy innovation. It was this blend of business and science that saw him selected as a finalist for the 2008 New Zealand Ernst and Young Entrepreneur of the Year and the 2011 recipient of the Royal Society of New Zealand's prestigious R.J. Scott medal.